MyFinsight
Home
Blog
About
Cash and cash
equivalents
$92,687K
(350.22%↑ Y/Y)
Marketable securities
$63,580K
(-46.09%↓ Y/Y)
Prepaid expenses and
other current assets
$4,405K
(-37.36%↓ Y/Y)
Fixed assets, gross
$2,658K
(5.69%↑ Y/Y)
Total current assets
$160,672K
(10.39%↑ Y/Y)
Operating lease
right-of-use assets
$3,055K
(23.78%↑ Y/Y)
Property and equipment,
net
$639K
(-19.82%↓ Y/Y)
Other assets
$480K
(-14.44%↓ Y/Y)
Restricted cash
$456K
(-24.75%↓ Y/Y)
Less accumulated
depreciation
$2,019K
(17.52%↑ Y/Y)
Total assets
$165,302K
(10.21%↑ Y/Y)
Total liabilities and
stockholders equity
$165,302K
(10.21%↑ Y/Y)
Total stockholders
equity
$127,382K
(6.28%↑ Y/Y)
Total liabilities
$37,920K
(25.84%↑ Y/Y)
Accumulated deficit
-$497,226K
(-53.17%↓ Y/Y)
Accumulated other
comprehensive gain (loss)
-$12K
(-33.33%↓ Y/Y)
Additional paid-in capital
$624,516K
(40.52%↑ Y/Y)
Total current
liabilities
$34,166K
(28.21%↑ Y/Y)
Operating lease
liabilities
$3,754K
(7.72%↑ Y/Y)
Common stock, 0.001 par
value per share...
$103K
(60.94%↑ Y/Y)
Preferred stock 0.001 par
value per share...
$1K
Accrued expenses
$25,367K
(18.81%↑ Y/Y)
Accounts payable
$7,597K
(82.23%↑ Y/Y)
Operating lease
liabilities, current
$1,202K
(6.47%↑ Y/Y)
Back
Back
Balance Sheet
Larimar Therapeutics, Inc. (LRMR)
Larimar Therapeutics, Inc. (LRMR)
source: myfinsight.com